Vicarious Surgical (NYSE:RBOT) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Vicarious Surgical (NYSE:RBOT) from a hold rating to a sell rating in a research note issued to investors on Saturday.

RBOT has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Vicarious Surgical in a research note on Wednesday, January 21st. BTIG Research reiterated a “neutral” rating on shares of Vicarious Surgical in a research report on Friday, December 12th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $7.00.

Vicarious Surgical Price Performance

Vicarious Surgical stock opened at $2.21 on Friday. The stock has a market capitalization of $14.48 million, a P/E ratio of -0.24 and a beta of 1.52. Vicarious Surgical has a 12-month low of $1.80 and a 12-month high of $16.35. The firm’s 50-day moving average is $2.50 and its two-hundred day moving average is $5.15.

Vicarious Surgical (NYSE:RBOT) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($1.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.37) by $0.46. As a group, analysts forecast that Vicarious Surgical will post -10.89 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its position in Vicarious Surgical by 22.1% during the third quarter. Dimensional Fund Advisors LP now owns 19,975 shares of the company’s stock valued at $110,000 after acquiring an additional 3,615 shares during the period. Connective Capital Management LLC acquired a new position in shares of Vicarious Surgical in the 3rd quarter valued at about $169,000. Finally, DNB Asset Management AS lifted its stake in shares of Vicarious Surgical by 12.1% in the 2nd quarter. DNB Asset Management AS now owns 29,199 shares of the company’s stock valued at $219,000 after purchasing an additional 3,154 shares in the last quarter. Institutional investors and hedge funds own 47.27% of the company’s stock.

Vicarious Surgical Company Profile

Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.

The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.